MSB 2.08% 94.0¢ mesoblast limited

Ann: Remestemcel Controlled Study in Crohns & Ulcerative Colitis, page-45

  1. 585 Posts.
    lightbulb Created with Sketch. 280
    the best thing about mesoblast is that when they finally have their breakthrough moment with the fda ( very soon) on any one of their many incredible product candidates (our first fda approval) , it will be followed by many more indications ... they have a stable of winners ready to follow...

    and as commercialization becomes a reality the process will improve and gather a rapid momentum

    I eagerly look forward to watching mesoblast future unfold , this will be a great Australian story!

    by starting more trials we will have continuity of cash flow for a very long time
    Last edited by googala: 22/10/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
94.0¢
Change
-0.020(2.08%)
Mkt cap ! $1.073B
Open High Low Value Volume
95.5¢ 97.0¢ 93.5¢ $1.424M 1.507M

Buyers (Bids)

No. Vol. Price($)
8 29390 93.5¢
 

Sellers (Offers)

Price($) Vol. No.
94.5¢ 14089 2
View Market Depth
Last trade - 16.10pm 13/09/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.